Full text is available at the source.
Abstract
Pyrimidine derivatives may offer diverse pharmacological profiles by targeting key pathways in diabetes treatment.
- Pyrimidine derivatives inhibit DPP-4 and modulate α-glucosidase/α-amylase activity.
- Mechanistic insights from molecular docking and quantitative structure-activity relationship studies reveal interactions with various antidiabetic targets.
- Higher efficacy, selectivity, and multitarget potential are associated with pyrimidine-based hybrids like morpholino-triazine and dihydropyrimidine-phthalimide.
- Clinical relevance is noted for specific compounds, including anagliptin and tolimidone.
- Emerging strategies such as AI-driven drug design may enhance the development of next-generation therapies.
Simplified